Abilify is a brand name for aripiprazole, an atypical antipsychotic medication prescribed to treat conditions such as schizophrenia, bipolar disorder, and major depressive disorder [1]. It is also used as an add-on treatment for irritability associated with autistic disorder [2]. The 10mg dosage is a common prescription strength for Abilify [3].
How does Abilify work?
Abilify functions as a dopamine partial agonist. It works by stimulating certain dopamine receptors while blocking others, helping to regulate dopamine activity in the brain [4]. This mechanism is believed to be responsible for its effectiveness in managing the symptoms of psychotic disorders and mood disorders [4].
When did Abilify's patent expire?
The primary patents for Abilify (aripiprazole) have expired, allowing for the availability of generic versions of the drug. The last of the key patents expired around 2017, though patent litigation and exclusivities can sometimes extend market protection for specific formulations or indications [5]. DrugPatentWatch.com tracks these patent expirations and exclusivities [5].
What are the generic alternatives to Abilify?
Following patent expirations, generic versions of aripiprazole became available. These generic options offer the same active ingredient and are therapeutically equivalent to brand-name Abilify, often at a lower cost [6]. Patients can typically ask their doctor or pharmacist about generic aripiprazole [6].
What are the side effects of Abilify?
Common side effects associated with Abilify can include nausea, vomiting, constipation, headache, dizziness, and weight gain [7]. More serious, though less common, side effects can include involuntary muscle movements (tardive dyskinesia), metabolic changes (like high blood sugar or cholesterol), and an increased risk of stroke in elderly patients with dementia-related psychosis [7]. Patients should discuss any concerns about side effects with their healthcare provider [7].
Can Abilify be used for conditions other than schizophrenia and bipolar disorder?
Yes, Abilify has received approval for additional uses beyond schizophrenia and bipolar disorder. It is indicated for the treatment of major depressive disorder as an adjunctive therapy, and for managing irritability in children and adolescents with autistic disorder [2].
What is the typical dosage for Abilify?
Dosage for Abilify varies depending on the condition being treated and the patient's individual response. For example, the starting dose for schizophrenia in adults might be 10mg to 15mg once daily, with a maximum dose of 30mg daily [1]. For bipolar mania, initial doses are often higher, such as 15mg once daily [1]. The 10mg dose is frequently used for maintenance therapy or for specific conditions like the add-on treatment for depression [1][3].
Who manufactures Abilify?
Brand-name Abilify was developed and is marketed by Otsuka Pharmaceutical [8]. However, with patent expirations, numerous pharmaceutical companies now manufacture and distribute generic aripiprazole [6].
What is the difference between Abilify and other antipsychotics?
Abilify is an atypical antipsychotic, a class that generally has a lower risk of certain side effects compared to older, typical antipsychotics, particularly extrapyramidal symptoms (movement disorders) [4]. Its partial agonist activity on dopamine D2 receptors is a key distinguishing feature, potentially offering a different balance of receptor occupancy and effects compared to other atypical antipsychotics which are typically pure antagonists [4].
What are the risks of taking Abilify?
Risks associated with Abilify include the potential for tardive dyskinesia, a serious movement disorder that may be irreversible [7]. It can also cause metabolic changes, such as hyperglycemia and diabetes, and potentially dyslipidemia [7]. There is also a warning about an increased risk of death in elderly patients with dementia-related psychosis treated with antipsychotics [7]. Patients should be monitored by their doctor for these potential risks [7].
Sources:
[1] https://www.abilify.com/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021427s040,021705s026,021811s028lbl.pdf
[3] https://www.drugs.com/abilify.html
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185067/
[5] https://www.drugpatentwatch.com/
[6] https://www.goodrx.com/aripiprazole
[7] https://www.mayoclinic.org/drugs-supplements/aripiprazole-oral-route/side-effects/drh-20061108
[8] https://www.otsuka.com/en/